Business Context and Reporting Period
Abbott Laboratories filed a Current Report on Form 8-K dated February 24, 2019. The filing reports a specific corporate finance event involving the redemption of senior notes by the Company and its subsidiary, St. Jude Medical, LLC.
Key Financial Metrics
The filing details the redemption of debt instruments rather than reporting operational financial performance metrics such as revenue, profit, or cash flow.
- Total Principal Redeemed: $499,997,000
- Abbott 2.800% Senior Notes (Due 2020): $483,689,000
- St. Jude Medical 2.800% Senior Notes (Due 2020): $16,308,000
- Redemption Price: 100.113% of aggregate principal amount plus accrued and unpaid interest.
Material Changes
The primary material change is the termination of the definitive agreements governing the aforementioned senior notes. The Company and St. Jude Medical fully redeemed the outstanding principal amounts of their respective 2.800% Senior Notes due 2020 on the Redemption Date of February 24, 2019.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or new risk factors. The transaction was executed in accordance with the terms of the existing indentures governing the notes. No unusual items or contingencies were disclosed beyond the standard redemption process.
Investor Verification Checklist
- Verify the total cash outflow required for the redemption, including the 0.113% premium and accrued interest.
- Confirm the impact of this debt reduction on the Company's total debt load and liquidity position.
- Review the Company's capital structure to understand the replacement of this debt or the use of cash reserves.
- Note that the filing does not contain operational results; refer to the most recent 10-Q or 10-K for revenue and earnings data.